Lymphoma studies by the Australasian Leukaemia and Lymphoma Group

Cooper, 1979, Non-Hodgkin’s lymphoma, Aust NZ J Med, 9, 459, 10.1111/j.1445-5994.1979.tb04182.x Lowenthal, 1984, How zealously should a patient with relapsed acute myeloid leukaemia be treated? Good survival after five simultaneous, potentially lethal, complications, Med J Aust, 140, 286, 10.5694/j.1326-5377.1984.tb104040.x Vincent, 1985, Low dose cytarabine in acute non-lymphoblastic leukaemia or myelodysplastic syndrome: report of six cases and review of the literature, Aust NZ J Med, 15, 10, 10.1111/j.1445-5994.1985.tb02722.x Stone J. A short history of the Australasian Leukaemia and Lymphoma Group. Australasian Leukaemia and Lymphoma Group Research Report 2011; 2012. A comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin’s lymphoma. Australia and New Zealand non-Hodgkin’s Lymphoma Cooperative Chemotherapy Study Group. Chair IA Cooper. Cancer Treatment Reports. vol. 66. 1982. p. 49–55. Ding, 1986, Investigation of the additive potential of teniposide and vincristine in non-Hodgkin’s lymphoma, Cancer Treat Rep, 70, 985 Matthews, 1992, Failure of intensive chemotherapy in poor prognosis non-Hodgkin’s lymphoma, Aust NZ J Med, 22, 123, 10.1111/j.1445-5994.1992.tb02790.x Cooper, 1994, Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin’s lymphoma. The Australian and New Zealand Lymphoma Group, J Clin Oncol, 12, 769, 10.1200/JCO.1994.12.4.769 Wolf, 1997, Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin’s lymphoma. The Australian and New Zealand Lymphoma Group, Ann Oncol, 8, 71, 10.1093/annonc/8.suppl_1.S71 Linch, 2010, Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65years with poor prognosis histologically aggressive NHL, Br J Haematol, 149, 237, 10.1111/j.1365-2141.2010.08081.x Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, 235, 10.1056/NEJMoa011795 Pfreundschuh, 2006, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, 379, 10.1016/S1470-2045(06)70664-7 Pfreundschuh, 2011, CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group, Lancet Oncol, 12, 1013, 10.1016/S1470-2045(11)70235-2 Cabanillas, 2011, Rituximab in DLBCL: 6years on, Lancet Oncol, 12, 984, 10.1016/S1470-2045(11)70251-0 Pfreundschuh, 2008, Lancet Oncol, 9, 435, 10.1016/S1470-2045(08)70078-0 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 Thieblemont, 2011, The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study, J Clin Oncol, 29, 4079, 10.1200/JCO.2011.35.4423 Gisselbrecht, 2012, Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma, J Clin Oncol, 30, 4462, 10.1200/JCO.2012.41.9416